CXCL10 and cancer: In this respect, in the absence of TPR-specific CD8pos T cells, the treatment of OvCAR3 and PC3M cancer cells with EpCAM-ReTARGTPRIFNαR149A inhibits proliferation and stimulates cancer cell-secreted CXCL10 (IP-10).